Key statistics
As of last trade Organon & Co (OGN*:MEX) traded at 343.00, -19.56% below its 52-week high of 426.40, set on Aug 26, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 343.00 |
---|---|
High | 343.00 |
Low | 343.00 |
Bid | 195.01 |
Offer | -- |
Previous close | 343.00 |
Average volume | -- |
---|---|
Shares outstanding | 257.54m |
Free float | 257.08m |
P/E (TTM) | 2.95 |
Market cap | 3.83bn USD |
EPS (TTM) | 5.04 USD |
Annual div (ADY) | 23.07 MXN |
---|---|
Annual div yield (ADY) | 6.73% |
Div ex-date | Nov 12 2024 |
Div pay-date | Dec 12 2024 |
Data delayed at least 20 minutes, as of Oct 30 2024 15:33 BST.
More ▼
Press releases
- Update on FDA Review of VTAMA® (tapinarof) Cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older
- Organon Reports Results for the Third Quarter Ended September 30, 2024
- US FDA Accepts Biologics License Application (BLA) for HLX14, Biosimilar Candidate of PROLIA/XGEVA (denosumab)
- Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
- Organon to Report Third Quarter 2024 Results and Host Conference Call on October 31, 2024
- Primary Endpoint Met in Phase 3 Comparative Clinical Study of Perjeta® (pertuzumab) Biosimilar Candidate HLX11
- Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
More ▼